Key result
Low-dose metronomic cyclophosphamide showed absent or moderate hematologic and intestinal toxicity compared to maximum tolerated dose regimens, though it caused sustained lymphopenia.
Why the study?
Does low-dose metronomic cyclophosphamide reduce toxicity on sensitive tissues compared to maximum tolerated dose cyclophosphamide?
Does low-dose metronomic cyclophosphamide reduce toxicity on sensitive tissues compared to maximum tolerated dose cyclophosphamide?
Low-dose metronomic cyclophosphamide offers clear safety advantages over conventional maximum tolerated dose chemotherapy, making it potentially ideal for long-term combination therapy with antiangiogenic drugs.
Answers are grounded in this paper and cite their sources.
May reduce toxicity versus MTD cyclophosphamide in animal models; leaves open translation to human antiangiogenic regimens.
The survival benefits of traditional maximum tolerated dose (MTD) cytotoxic therapy have been modest for the treatment of most types of metastatic malignancy and, moreover, often come with increased acute and chronic toxicity. Recent studies have demonstrated that the frequent administration of comparatively low doses of cytotoxic agents, with no extended breaks [low-dose metronomic (LDM) chemotherapy], may not only be at least as efficient as MTD therapy but also less toxic. This coincides with an apparent selectivity for "activated" endothelial cells of the tumor vasculature. However, the impact of LDM chemotherapy on the most sensitive target cell populations normally affected by MTD therapy (i.e., bone marrow progenitors, gut mucosa, and hair follicle cells) has not been analyzed in experimental detail. Therefore, we compared effects of LDM and MTD cyclophosphamide (CTX) on bone marrow and gut mucosa. Furthermore, we studied the potential impact of LDM CTX on angiogenesis in the context of wound healing and evidence of organ toxicity. We show absent or moderate hematologic and intestinal toxicity of LDM as opposed to MTD CTX. Of note was the finding of sustained lymphopenia, which is not unexpected given the use of CTX as immunosuppressive drug. There was no negative impact on wound healing or evidence of organ toxicity. LDM offers clear safety advantages over conventional MTD chemotherapy and therefore would appear to be ideal for long-term combination therapy with targeted antiangiogenic drugs.
No takes yet. Share an insight, caveat, or question.
Emmenegger et al. (2004) studied Metastatic malignancy. Low-dose metronomic cyclophosphamide vs. Maximum tolerated dose cyclophosphamide was evaluated on Toxicity on bone marrow, gut mucosa, wound healing, and organ toxicity. Low-dose metronomic cyclophosphamide showed absent or moderate hematologic and intestinal toxicity compared to maximum tolerated dose regimens, though it caused sustained lymphopenia.
Synapse has enriched 10 related papers. Consider them for comparative context: